Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2022-11-30 Earnings Release
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release dated November 30, 2022, announcing that MedinCell received a \$4 million payment from the Bill & Melinda Gates Foundation to fund the next development stages of its injectable contraceptive program (mdc-WWM), specifically aiming for a Phase 1 clinical trial launch by the end of 2023. This announcement details financial milestones related to a grant/partnership and provides updates on product development and market potential. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a transcript (CT). It is a specific announcement regarding financial progress tied to development milestones, which aligns best with an Earnings Release (ER) if it were quarterly results, or a Capital/Financing Update (CAP) due to the specific funding milestone. However, since it is a press release announcing a specific financial receipt tied to R&D progress, and not a general earnings summary, it functions as a key operational/financial update. Given the options, it is a specific announcement of financial progress related to a partnership, which often falls under Earnings Release (ER) for key operational highlights, or potentially Capital/Financing Update (CAP). Since it focuses heavily on the receipt of funds and the next steps, 'ER' (Earnings Release - initial announcement of periodical/key financial results/milestones) is a strong fit, as these press releases often precede formal quarterly filings. Alternatively, 'CAP' (Capital/Financing Update) is also plausible due to the focus on the \$4M payment. Given the context of a press release detailing a specific financial milestone and operational progress, 'ER' is often used for such immediate announcements, even if not strictly quarterly earnings figures. However, because the core subject is receiving funding/a grant milestone, 'CAP' is more precise than a general 'ER' which usually covers revenue/profit/loss. I will classify it as 'CAP' as it is a direct update on financing/capital structure progress via a grant milestone. Q4 2022
2022-11-30 French
Inside Information / Other news releases
Capital/Financing Update Classification · 99% confidence The document is a press release dated November 23, 2022, announcing the execution of a new credit facility of 40 million euros with the European Investment Bank (EIB). It details the terms, tranches, repayment schedules, interest rates, and associated warrants (potential dilution). This content directly relates to the company's fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition of 'Capital/Financing Update' (Code: CAP). It is not an earnings release (ER), an interim report (IR), or a full annual report (10-K). Since it is a detailed announcement of a financing event, CAP is the most appropriate classification.
2022-11-23 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is a press release dated November 23, 2022, detailing the finalization of a financing agreement between MedinCell and the European Investment Bank (EIB) for a new €40 million credit facility. It discusses the terms of the loan, repayment schedules, potential dilution from warrants (BSA), and the impact on the company's cash visibility. This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it is highly specific to a financing event.
2022-11-23 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 98% confidence The document is a press release announcing a new 40 million Euro loan agreement between the European Investment Bank (EIB) and MedinCell, intended to support the development of long-acting injectable treatments. This announcement details a financing activity (a loan agreement) and its purpose, which directly aligns with the definition of a Capital/Financing Update. It is not a full annual report (10-K), an earnings release (ER), or a transcript (CT). Since it is an announcement about securing funding, the most appropriate code is CAP.
2022-11-23 French
Inside Information / Other news releases
Capital/Financing Update Classification · 98% confidence The document is a press release dated November 23, 2022, announcing a new €40 million loan agreement between EIB and MedinCell to support the development of innovative treatments. It details the purpose of the financing, quotes executives, and provides background information on the involved entities (EIB, MedinCell, EFSI). This type of announcement, focusing on fundraising, financing activities, and capital structure support from external lenders, directly aligns with the definition of 'Capital/Financing Update'. It is not a formal regulatory report like a 10-K, an earnings release (ER), or a proxy statement (DEF 14A). Therefore, the appropriate code is CAP.
2022-11-23 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of October 31st. This content directly relates to changes in the total number of shares outstanding and voting power, which falls under Share Issue/Capital Change (SHA) or potentially a specific regulatory filing. Given the focus on the total number of shares and voting rights, SHA is the most precise fit, as it covers capital structure changes, which includes the total count of shares.
2022-11-16 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.